Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany

Tilman Hans Steinmetza Center for Hematology and Oncology, Cologne, GermanyCorrespondence[email protected]

https://orcid.org/0000-0001-8580-3109

Moushmi Singhb Amgen Limited, Uxbridge, UK

Andrea Lebiodac Amgen GmbH, Munich, Germany

Leah Finkd Kantar, Health Division, Paris, France

Martina Schoehlc Amgen GmbH, Munich, Germany

Achim Riethc Amgen GmbH, Munich, Germany

Sebastian Gonzalez-McQuiree Amgen (Europe) GmbH, Rotkreuz, Switzerland

Monika Engelhardtf Faculty of Freiburg, University Hospital of Freiburg, Freiburg, Germany

show all

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (6)

Larysa SanchezAjai ChariMu ChengDasha CherepanovMaral DerSarkissianFei HuangDawn Marie StullJonathan DaboraMelanie YoungStephen J. NogaSelina PiMelody ZhangAzeem BanatwalaMei Sheng DuhSikander Ailawadhi. (2023) Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. Journal of Managed Care & Specialty Pharmacy 29:11, pages 1205-1218.
Crossref

Joaquín Martínez-Lopez, Abigail Bailey, Annabel Lambert, Emily Luke, Amanda Ribbands, Nichola Erler-Yates, Satish Valluri, Benjamin Haefliger & Francesa Gay. (2023) Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe. Future Oncology 19:31, pages 2103-2121.
Crossref

Enrique M. Ocio, Carmen Montes-Gaisán, Gabriela Bustamante, Sebastián Garzón, Esther González, Ernesto Pérez-Persona, Verónica González-Calle, Maialen Sirvent, José M. Arguiñano, Yolanda González, Rafael Ríos, Dunia de Miguel, Marta Grande, Alonso Fernández-Nistal, Andrea Naves & Laura Rosiñol. (2023) Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study. Clinical Lymphoma Myeloma and Leukemia.
Crossref

Shinsuke Iida, Tadao Ishida, Toshihiro Miyamoto, Satoshi Teramukai, Heigoroh Shirai, Rie Kanamori, Yuki Tajima, Bruce Crawford, Jingbo Yi & Takanori Teshima. (2022) MEdical Database AnaLysIS of Japanese multiple myeloma patienTs with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantation. International Journal of Hematology 116:3, pages 411-422.
Crossref

H. Tilman Steinmetz, Moushmi Singh, Joseph Milce, Mohamad Haidar, Achim Rieth, Andrea Lebioda & Jörn Kohnke. (2022) Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany. Advances in Therapy 39:3, pages 1247-1266.
Crossref

Cyrille Touzeau, Nadia Quignot, Jie Meng, Heng Jiang, Artak Khachatryan, Moushmi Singh, Vanessa Taieb, Jean-Vannak Chauny & Gaëlle Désaméricq. (2021) Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS). Annals of Hematology 100:7, pages 1825-1836.
Crossref

Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany

Articles from other publishers (6)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany

Citations (6)

Articles from other publishers (6)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date